Genomic alterations in neuroendocrine cancers of the ovary. - Wikidata - wikimedia - TriplyDB

Genomic alterations in neuroendocrine cancers of the ovary.

Genomic alterations in neuroendocrine cancers of the ovary.

http://www.wikidata.org/entity/Q37212060

about

Expanding the search for significant EGFR mutations in NSCLC outside of the tyrosine kinase domain with next-generation sequencing.Primary ovarian small cell carcinoma of pulmonary type with coexisting endometrial carcinoma in a breast cancer patient receiving tamoxifen: A case report and literature review.

P2860

Q52767309-EA9F2110-AFD2-4785-96DA-04EC4A5858C6 Q55278871-E2A2310A-3873-452C-B3AA-D4175519A897

P2860

Genomic alterations in neuroendocrine cancers of the ovary.

http://www.wikidata.org/entity/Q37212060

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 August 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Genomic alterations in neuroendocrine cancers of the ovary.

@en

Genomic alterations in neuroendocrine cancers of the ovary.

@nl

type

label

Genomic alterations in neuroendocrine cancers of the ovary.

@en

Genomic alterations in neuroendocrine cancers of the ovary.

@nl

prefLabel

Genomic alterations in neuroendocrine cancers of the ovary.

@en

Genomic alterations in neuroendocrine cancers of the ovary.

@nl

P1433

Q37212060-04F4E39C-015B-4D59-B1BF-1DA06AC387A1

P1476

Q37212060-2167F6EC-6B7D-40FD-BE1A-790F09CA7B58

P2093

Q37212060-2C05E946-3C42-4C8A-9C89-FC40F1819B8C

Q37212060-5273E61F-7CAF-452B-B7DE-45C8D6D109B2

Q37212060-5AF3A2FB-8FCC-486B-9070-011B2F68FAB4

Q37212060-6BF354F7-2C4B-49E0-8B35-3217735411C5

Q37212060-768ACD11-1DF9-4916-9C04-D71ECAE78B73

Q37212060-D71BE334-EA16-4F7D-AE61-E7D9CE5BE7B4

Q37212060-DB1B7929-4390-45C4-BDF3-5D825EAB0D01

Q37212060-E72D38EA-D3E1-4673-9366-8D8E2CD5CBB1

P2860

Q37212060-144E7F13-F9DF-4536-954A-A821E47C8A33

Q37212060-1B3E090F-53DF-4673-B6BA-B7299B1A8770

Q37212060-268E449A-812C-4056-8DDA-60D7F9623687

Q37212060-35D65EE0-2492-430E-B173-EA8053274E89

Q37212060-362BB746-E97E-4D06-A7F2-539B72018338

Q37212060-446FBAE5-D928-4DFD-856C-8BE85DA7ED8E

Q37212060-7B9D5E8B-2E01-4399-9FAD-6D221BED30F3

Q37212060-7BFAF7D4-04A1-48BD-BFF2-0A2564F1EE1E

Q37212060-7D39BC1B-D1D7-4017-8D48-377938E9F5B3

Q37212060-7EF36888-1255-44CC-AD54-1C9416883A50

P2888

Q37212060-92366874-0465-4172-8014-FF16182DDF8D

P304

Q37212060-F8FCF528-8470-4DC9-B457-5691C4669BFF

P31

Q37212060-377AF53E-CF7D-4750-BBE5-C011C712FF91

P356

Q37212060-2A981F22-DCAC-48EC-A0EB-A831D906FCA4

P433

Q37212060-8F20FEDE-138C-45B3-B209-D59552A99B20

P478

Q37212060-C25FA915-57A7-4847-8571-E51E1D12FE89

P577

Q37212060-150D37CF-D578-4409-BDEB-E474F9769D28

P6179

Q37212060-E4EC610D-6860-4E09-B94D-12BBE1337321

P698

Q37212060-8C8411BD-15F8-4723-B713-8745226215F3

P932

Q37212060-97766834-A0D0-4344-9BFA-48DB726A9B2E

P356

S13048-016-0259-2

P1433

Journal of Ovarian Research

P1476

Genomic alterations in neuroendocrine cancers of the ovary.

@en

P2093

Eric Wiedower

http://www.w3.org/2001/XMLSchema#string

George Yaghmour

http://www.w3.org/2001/XMLSchema#string

Jason C Chandler

http://www.w3.org/2001/XMLSchema#string

Manjari Pandey

http://www.w3.org/2001/XMLSchema#string

Mike G Martin

http://www.w3.org/2001/XMLSchema#string

Omer Hassan Jamy

http://www.w3.org/2001/XMLSchema#string

Philippe Prouet

http://www.w3.org/2001/XMLSchema#string

Rebecca Feldman

http://www.w3.org/2001/XMLSchema#string

P2860

Recurrent SMARCA4 mutations in small cell carcinoma of the ovary.

Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.

Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4

MGMT testing allows for personalised therapy in the temozolomide era.

Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer

ERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and/or gemcitabine.

F14512, a polyamine-vectorized inhibitor of topoisomerase II, exhibits a marked anti-tumor activity in ovarian cancer.

Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type.

Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide.

TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer.

P2888

s13048-016-0259-2

P304

52

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13048-016-0259-2

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1024466978

http://www.w3.org/2001/XMLSchema#string

P698

27566252

http://www.w3.org/2001/XMLSchema#string

P932

5002197

http://www.w3.org/2001/XMLSchema#string